Immunovant's Upcoming Presentation Highlights Phase 2 Study
NEW YORK — Immunovant, Inc. (NASDAQ: IMVT), a leading clinical-stage immunology company, is gearing up for an important participation at the upcoming American Thyroid Association (ATA) Annual Meeting. This prestigious event is scheduled for early November, where the company will share critical findings from its Phase 2a clinical trial on batoclimab, specifically focused on its efficacy in treating Graves’ disease.
Details on the Presentation of Batoclimab
The oral presentation is set to feature a late-breaking abstract that highlights novel data surrounding both thyroid-specific and extrathyroidal manifestations of Graves’ disease. Attendees can expect a detailed examination of how batoclimab, an FcRn inhibitor, acts on the thyroidal and extrathyroidal symptoms of this autoimmune condition.
Presentation Overview
The specifics of the presentation are as follows:
- Title: Efficacy and Safety of the FcRn Inhibitor, Batoclimab, in Graves’ Thyroidal and Extrathyroidal Disease: a Proof-of-concept Study
- Presentation Number: #0020
- Session: #5 – Autoimmune Thyroid Disease
- Date and Time: Friday, November 1, 2024, 4:05 PM – 5:05 PM ET
- Presenter: Dr. George Kahaly, MD, PhD
Understanding Graves’ Disease
Graves’ disease is a prevalent autoimmune disorder that leads to the overproduction of thyroid hormones, making it the most common cause of hyperthyroidism. It predominantly affects women under the age of 40. In individuals with this condition, the body produces harmful IgG autoantibodies, which bind to thyroid-stimulating hormone receptors, resulting in excessive hormone production. Traditional treatment options, including antithyroid medications, radioactive iodine, and surgical interventions, have remained largely unchanged for over seven decades.
About Immunovant, Inc.
Immunovant, Inc. is at the forefront of developing innovative therapies aimed at transforming the management of autoimmune diseases. Their anti-FcRn technology serves as a platform for creating tailored treatments that address the diverse needs of patients suffering from such conditions. The company's commitment to enhancing the quality of life for these individuals drives their research and development efforts.
Further Information
For those interested in learning more about Immunovant, please reach out directly via their official communication channels.
Contact Information:
Renee Barnett, MBA
Chief Financial Officer
Immunovant, Inc.
Email: info@immunovant.com
Frequently Asked Questions
What is the significance of the upcoming presentation?
The presentation at the ATA Annual Meeting will showcase critical findings from a Phase 2 clinical trial, which could influence treatment approaches for Graves’ disease.
Who will be presenting the findings?
Dr. George Kahaly, MD, PhD, will present the late-breaking abstract concerning batoclimab’s efficacy.
What is Graves’ disease?
Graves' disease is an autoimmune disorder characterized by the overproduction of thyroid hormones, leading to hyperthyroidism.
What treatments exist for Graves’ disease?
Current treatments include antithyroid drugs, radioactive iodine, and surgical options, all aimed at reducing thyroid hormone levels.
How is Immunovant, Inc. contributing to autoimmune disease treatment?
Immunovant is pioneering therapies based on anti-FcRn technology, which seeks to offer more effective solutions for individuals affected by autoimmune diseases.
